Published in Cancer Weekly, May 19th, 2009
"We investigated the effectiveness of superfine dispersed lentinan in advanced pancreatic cancer patients in a multi-center study. Twenty-nine patients with unresectable and recurrent pancreatic cancer were enrolled, and adverse events and quality of life scores were assessed. Survival times were evaluated according to results of a 3-year follow-up survey. Although a diarrhea of grade-1 adverse event dependent on the test article...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.